Blood Culture Tests Industry Worth $8.94 billion by 2031
The report "Blood Culture Tests Market by Product (Consumables, Instruments), Method (Manual, Automated), Technology (Culture-Based, Molecular, Proteomics), Application (Bacteremia, Fungemia), End User (Hospital, Academic Research), Region - Global Forecast to 2031" is projected to be valued at USD 6.66 billion in 2026 and USD 8.94 billion by 2031, exhibiting a CAGR of 6.1%.
Browse 320 market data Tables and 50 Figures spread through 250 Pages and in-depth TOC on "Blood Culture Tests Market, by Product (Consumables, Instruments), Method (Manual, Automated), Technology (Culture-Based, Molecular, Proteomics), Application (Bacteremia, Fungemia), End User (Hospital, Academic Research), Region - Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/blood-culture-test-market-159606753.html
The global blood culture tests market is mainly driven by the rising burden of bloodstream infections (BSIs) and sepsis, increasing prevalence of healthcare-associated infections (HAIs), and growing concerns regarding antimicrobial resistance (AMR). Increasing hospital and critical care admissions, expanding diagnostic laboratory infrastructure, and the growing clinical emphasis on early pathogen detection and appropriate antimicrobial therapy are further supporting market growth. Moreover, the increasing adoption of automated blood culture systems, laboratory automation, and rapid pathogen identification and antimicrobial susceptibility testing technologies is expected to offer growth opportunities for market players during the forecast period.
Culture-based segment captured the largest share of the blood culture tests market in 2025.
The blood culture tests market, by technology, is classified into culture-based, molecular, and proteomics. Among these, the culture-based segment accounted for the largest market share in 2025. The dominance of this segment is primarily attributed to the widespread use of conventional and automated blood culture methods as the established standard for detecting viable microorganisms in bloodstream infections (BSIs). Culture-based technologies enable the recovery of bacterial and fungal pathogens from blood specimens and provide isolates for subsequent organism identification and antimicrobial susceptibility testing (AST), supporting targeted antimicrobial therapy.
Hospital laboratories segment to record the highest CAGR from 2026 to 2031.
The blood culture tests market, by end user, is segmented into hospital laboratories, reference laboratories, academic research laboratories, and other end users. Among these, the hospital laboratories segment is projected to grow at the highest rate during the forecast period, owing to the high volume of blood culture testing generated by hospitalized patients with suspected sepsis and bloodstream infections. Hospitals, particularly those with emergency departments, intensive care units, oncology units, transplant centers, and other high-acuity settings, routinely require blood cultures to support early diagnosis and antimicrobial treatment decisions. They also represent a major installed base for automated blood culture instruments, generating sustained demand for blood culture bottles, media, reagents, and associated microbiology solutions. Increasing hospital and critical care admissions, growing emphasis on sepsis management and antimicrobial stewardship, and continued investments in automated microbiology laboratory infrastructure further support the segment’s dominant market position.
North America to be the second-fastest-growing region between 2026 and 2031.
The blood culture tests market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to grow at a significant rate in the blood culture tests market during the forecast period, supported by its advanced clinical microbiology infrastructure, high healthcare expenditure, and widespread adoption of automated blood culture technologies. The region has an extensive network of hospital and reference laboratories equipped with advanced microbiology platforms, supporting high testing volumes and recurring demand for blood culture consumables. In addition, the burden of sepsis, bloodstream infections, healthcare-associated infections, and antimicrobial resistance, along with strong emphasis on antimicrobial stewardship and timely pathogen identification, continues to support market demand. The presence of established diagnostic companies, continued investments in laboratory automation and rapid microbial identification, and early adoption of advanced infectious disease diagnostics further reinforce its leading position in the global market.
Major players operating in blood culture tests market are Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), DiaSorin S.p.A. (Italy), Bruker Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Accelerate Diagnostics, Inc (US), and Autobio Diagnostics Co., Ltd (China), among others.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Blood Culture Tests Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
